- Home
- THRD vs SABA Comparison
THRD vs SABA Comparison
Compare THRD & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRD
- SABA
- Stock Information
- Founded
- THRD 2019
- SABA 1988
- Country
- THRD United States
- SABA United States
- Employees
- THRD N/A
- SABA N/A
- Industry
- THRD Biotechnology: Pharmaceutical Preparations
- SABA
- Sector
- THRD Health Care
- SABA
- Exchange
- THRD Nasdaq
- SABA Nasdaq
- Market Cap
- THRD 238.7M
- SABA 260.0M
- IPO Year
- THRD 2022
- SABA N/A
- Fundamental
- Price
- THRD $5.46
- SABA $9.13
- Analyst Decision
- THRD Hold
- SABA
- Analyst Count
- THRD 3
- SABA 0
- Target Price
- THRD $5.00
- SABA N/A
- AVG Volume (30 Days)
- THRD 220.4K
- SABA 290.0K
- Earning Date
- THRD 08-07-2025
- SABA 01-01-0001
- Dividend Yield
- THRD N/A
- SABA 12.91%
- EPS Growth
- THRD N/A
- SABA N/A
- EPS
- THRD N/A
- SABA N/A
- Revenue
- THRD N/A
- SABA N/A
- Revenue This Year
- THRD N/A
- SABA N/A
- Revenue Next Year
- THRD N/A
- SABA N/A
- P/E Ratio
- THRD N/A
- SABA N/A
- Revenue Growth
- THRD N/A
- SABA N/A
- 52 Week Low
- THRD $3.18
- SABA $3.64
- 52 Week High
- THRD $16.02
- SABA $4.42
- Technical
- Relative Strength Index (RSI)
- THRD 66.73
- SABA 64.47
- Support Level
- THRD $5.42
- SABA $9.08
- Resistance Level
- THRD $5.45
- SABA $9.29
- Average True Range (ATR)
- THRD 0.04
- SABA 0.11
- MACD
- THRD -0.01
- SABA -0.00
- Stochastic Oscillator
- THRD 50.00
- SABA 69.70
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.